Compare FSTR & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSTR | CMPS |
|---|---|---|
| Founded | 1902 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.8M | 778.7M |
| IPO Year | 1995 | 2020 |
| Metric | FSTR | CMPS |
|---|---|---|
| Price | $27.93 | $5.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $32.00 | $27.14 |
| AVG Volume (30 Days) | 18.4K | ★ 3.0M |
| Earning Date | 03-03-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.86 |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $540,009,000.00 | N/A |
| Revenue This Year | $5.44 | N/A |
| Revenue Next Year | $3.05 | N/A |
| P/E Ratio | $40.81 | ★ N/A |
| Revenue Growth | ★ 1.74 | N/A |
| 52 Week Low | $17.16 | $2.25 |
| 52 Week High | $32.63 | $8.90 |
| Indicator | FSTR | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 33.53 |
| Support Level | $27.26 | $4.78 |
| Resistance Level | $27.95 | $7.02 |
| Average True Range (ATR) | 1.27 | 0.41 |
| MACD | -0.19 | -0.18 |
| Stochastic Oscillator | 19.27 | 0.48 |
L.B. Foster Co is a technology solutions provider of products and services for the rail and infrastructure markets. The company has two reporting segments: Rail, Technologies, and Services (Rail); and Infrastructure Solutions (Infrastructure). Maximum revenue is generated from the Rail segment, which is comprised of several manufacturing and distribution businesses that provide products and services for freight and passenger railroads and industrial companies throughout the world. The Infrastructure segment offers engineered precast concrete solutions, as well as fabricated bridge, protective pipe coating, and pipe threading offerings across North America. Geographically, the company generates maximum revenue from the United States, followed by Canada, the UK, and other markets.
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.